Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
AssigneeLudwig Institute for Cancer Research
InventorsJean-Jacques Patard, Francis Brasseur, Thierry Boon-Falleur
Life of this patent
Estimating the term…
Abstract
A method for screening for bladder cancer by identifying expression of one or more of MAGE-1, MAGE-2, MAGE-3 and MAGE-4 is the disclosed invention. Expression can be determined by a number of methods, including nucleotide amplification assays.
Claims7
Method for screening for bladder cancer in a subject, comprising assaying a bladder tissue sample from a subject to determine expression of mRNA of at least one member of the group of genes encoding MAGE-1, MAGE-2, MAGE-3 and MAGE-4 tumor rejection antigen precursors, wherein expression of said mRNA is an indication of possibility of bladder cancer in said subject.
Method for screening for bladder cancer in a subject, comprising assaying a bladder tissue sample from a subject to determine presence of at least one member of the group of MAGE-1, MAGE-2, MAGE-3 and MAGE-4 tumor rejection antigen precursors in said sample is an indication of possibility of bladder cancer in said subject.
Method for monitoring status of a bladder cancer comprising:
- (i) assaying a sample of bladder cancer cells taken from a subject with bladder cancer to determine expression of mRNA for at least one member of the group of genes encoding MAGE-1, MAGE-2 MAGE-3 and MAGE-4 tumor rejections antigen precursors, to determine a value, wherein said value is the level of mRNA expression in said sample and
- (ii) comparing the value determined in (i) to a value determined previously for the member or members of the group of genes encoding MAGE-1, MAGE-2, MAGE-3 and MAGE-4 tumor rejection antigen precursors obtained the same way the value in (i) was determined, wherein a change in the value obtained in (i) as compared to the value determined previously shows a change in status of said bladder cancer.
Dependencies are inferred from the claim text.